Molecular effects of C-peptide in microvascular blood flow regulation

Review of Diabetic Studies

Volumn 6, Issue 3, 2009, Pages 159-167

  Forst, Thomas ^a,b   Hach, Thomas ^c   Kunt, Thomas ^d   Weber, Matthias M ^b   Pfützner, Andreas ^a  

^a Institute for Clinical Research and Development   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c MCKINSEY AND COMPANY   (United States)

^d Diabetes Centre   (Germany)

Author keywords

C peptide; Endothelial nitric oxide; Erythrocyte deformability; G protein; Microvascular blood flow; NF kappaB; Smooth muscle; Type 1 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); C PEPTIDE; NITRIC OXIDE;

BLOOD FLOW; DIABETIC MICROANGIOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM CELL; ERYTHROCYTE; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTE FUNCTION AND CHARACTERISTICS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; MICROVASCULARIZATION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN STRUCTURE; REVIEW; SKIN BLOOD FLOW; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 76149125484     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2009.6.159     Document Type: Review

References (65)

1. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003. 26:832-836.
2. Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O, Grassi G, Cavallo-Perin P, Bruno G. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009. 32(2):301-305.
3. Delaney C, Shaw J, Day T. Acute, local effects of iontophoresed insulin and C-peptide on cutaneous microvascular function in Type 1 diabetes mellitus. Diabet Med 2004. 21:428-433.
4. Kitamura T, Kimura K, Jung BD, Makondo K, Sakane N, Yoshida T, Saito M. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells. Biochem J 2002. 366(Pt 3):737-744.
5. Forst T, De La Tour DD, Kunt T, Pfützner A, Goitom K, Pohlmann T, Schneider S, Johansson BL, Wahren J, Löbig M, Engelbach M, Beyer J, Vague P. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 2000. 98(3):283-290.
6. Forst T, Kunt T, Pohlmann T, Goitom K, Engelbach M, Beyer J, Pfützner A. Biological activity of C-peptide on the skin microcirculation in patients with insulindependent diabetes mellitus. J Clin Invest 1998. 101(10):2036-2041.
7. Scalia R, Coyle KM, Levine BJ, Booth G, Lefer AM. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J 2000. 14(14):2357-2364.
8. Young LH, Ikeda Y, Scalia R, Lefer AM. C-peptide exerts cardioprotective effects in myocardial ischemiareperfusion. Am J Physiol Heart Circ Physiol 2000. 279:H1453-H1459.
9. Cifarelli V, Luppi P, Tse HM, He J, Piganelli J, Trucco M. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappaB activation in vascular smooth muscle cells. Atherosclerosis 2008. 201:248-257.
10. Luppi P, Cifarelli V, Tse H, Piganelli J, Trucco M. Human C-peptide antagonises high glucose-induced endothelial dysfunction through the nuclear factor-kappaB pathway. Int J Obes Relat Metab Disord 2008. 51:1534-1543.
11. Marx N, Walcher D, Raichle C, Aleksic M, Bach H, Grüb M, Hombach V, Libby P, Zieske A, Homma S, Strong J. C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol 2004. 24(3):540-545.
12. Forst T, Hohberg C, Pfützner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009. 41:123-131.
13. Tibirica E, Rodrigues E, Cobas R, Gomes MB. Impairment of skin capillary recruitment precedes chronic complications in patients with type 1 diabetes. Rev Diabet Stud 2007. 4(2):85-88.
14. Forst T, Pfützner A, Kunt T, Pohlmann T, Schenk U, Bauersachs R, Küstner E, Beyer J. Skin microcirculation in patients with type I diabetes with and without neuropathy after neurovascular stimulation. Clin Sci (Lond) 1998. 94(3):255-261.
15. Kunt T, Forst T, Harzer O, Buchert G, Pfützner A, Löbig M, Zschäbitz A, Stofft E, Engelbach M, Beyer J. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes 1998. 106(3):183-188.
16. Ernst E, Matrai A. Altered red and white blood cell rheology in type II diabetes. Diabetes 1986. 35:1412-1415.
17. Barnes AJ, Locke O, Scudder PR, Dormandy TL, Slack J. Is hyperviscosity a treatable component of diabetic microcirculatory disease. Lancet 1977. 2.2:789-791.
18. +)ATPase activity in type 1 (insulin-dependent) diabetic subjects. Diabetologia 1986. 29:623-628.
19. McMillan DE, Utterback NG, LaPuma J. Reduced erythrocyte deformability in diabetes. Diabetes 1998. 27:895-901.
20. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001. 22:36-52.
21. Kuo L, Davis MJ, Chilian WM. Myogenic activity in isolated subepicardial and subendocardial coronary arterioles. Am J Physiol 1988. 255:H1558-H1562.
22. Colwell JA, Lopes-Virella MF. A review of the development of large-vessel disease in diabetes mellitus. Am J Med 1988. 85:113-118.
23. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980. 288:373-376.
24. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endotheliumderived relaxing factor. Nature 1987. 327:524-526.
25. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995. 38:1337-1344.
26. Pieper GM, Siebeneich W, Moore-Hilton G, Roza AM. Reversal by L-arginine of a dysfunctional arginine/ nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia 1997. 40:910-915.
27. McNally PG, Watt PAC, Rimmer T, Burden AC, Hearnshaw JR, Thurston H. Impaired contraction and endothelium-dependent relaxation in isolated resistance vessels from patients with insulin-dependent diabetes mellitus. Clin Sci 1994. 87:31-36.
28. Kamata K, Miyata N, Abiru T, Kasuya Y. Functional changes in vascular smooth muscle and endothelium of arteries during diabetes mellitus. Life Sci 1992. 50:1379-1387.
29. Johnstone MT, Craeger SJ, Scales KM, Cusco JA, Lee BA, Craeger MA. Impaired endothelium-dependent vasodilatation in patients with insulin-dependent diabetes mellitus. Circulation 1993. 88:2510-2516.
30. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994. 23(6 Pt 2):1121-1131.
31. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993. 329:2002-2012.
32. Wallerath T, Kunt T, Forst T, Closs EI, Lehmann R, Flohr T, Gabriel M, Schäfer D, Göpfert A, Pfützner A, Beyer J, Förstermann U. Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide. Nitric Oxide 2003. 9(2):95-102.
33. Kunt T, Schneider S, Pfützner A, Goitum K, Engelbach M, Schauf B, Beyer J, Forst T. The effect of human proinsulin C-peptide on erythrocyte deformability in patients with type 1 diabetes mellitus. Diabetologia 1999. 42(4):465-471.
34. Jensen ME, Messina EJ. C-peptide induces a concentration-dependent dilation of skeletal muscle arterioles only in presence of insulin. Am J Physiol 1999. 276:H1223-H1228.
35. Ohtomo Y, Bergman T, Johansson BL, Jornvall H, Wahren J. Differential effects of proinsulin C-peptide fragments on Na+, K+- ATPase activity of renal tubule segments. Diabetologia 1998. 41:287-291.
36. Chien S. Red cell deformability and its relevance to blood flow. Annu Rev Physiol 1987. 49:177-192.
37. Shafqat J, Juntti-Berggren L, Zhong Z, Ekberg K, Köhler M, Berggren PO, Johansson J, Wahren J, Jörnvall H. Proinsulin C-peptide and its analogues induce intracellular Ca2+ increases in human renal tubular cells. Cell Mol Life Sci 2002. 59(7):1185-1189.
38. Parthasarathi K, Lipowsky HH. Capillary recruitment in response to tissue hypoxia and its dependence on red blood cell deformability. Am J Physiol 1999. 277:H2145-H2157.
39. Bareford D, Jennings PE, Stone PC, Baar S, Barnett AH, Stuart J. Effects of hyperglycaemia and sorbitol accumulation on erythrocyte deformability in diabetes mellitus. J Clin Pathol 1986. 39:722-727.
40. Cho YI, Mooney MP, Cho DJ. Hemorheological disorders in diabetes mellitus. J Diabetes Sci Technol 2008. 2:1130-1138.
41. Rigler R, Pramanik A, Jonasson P, Kratz G, Jansson OT, Nygren P, Stahl S, Ekberg K, Johansson B, Uhlen S, Uhlen M, Jörnvall H, Wahren J. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci U S A 1999. 96(23):13318-13323.
42. Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath WF, DiMarchi RD, Di Cera E, Williamson JR. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997. 277(5325):563-566.
43. Hach T, Forst T, Kunt T, Ekberg K, Pfützner A, Wahren J. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients. Exp Diabetes Res 2008. 2008:730594.
44. Zhong Z, Davidescu A, Ehren I, Ekberg K, Jörnvall H, Wahren J, Chibalin AV. C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells. Diabetologia 2005. 48(1):187-197.
45. Meyer JA, Froelich JM, Reid GE, Karunarathne WK, Spence DM. Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter. Diabetologia 2008. 51(1):175-182.
46. Meyer JA, Subasinghe W, Sima AA, Keltner Z, Reid GE, Daleke D, Spence DM. Zinc-activated C-peptide resistance to the type 2 diabetic erythrocyte is associated with hyperglycemia-induced phosphatidylserine externalization and reversed by metformin. Mol Biosyst 2009. 5(10):1157-1162.
47. Simmons DA, Kern EF, Winegrad AI, Martin DB. Basal phosphatidylinositol turnover controls aortic Na+/K+ ATPase activity. J Clin Invest 1986. 77:503-513.
48. +-pump inhibitors and membrane depolarizing agents on acetycholine-induced endothelium dependent relaxation and cyclic GMP accumulation in rat aorta. Eur J Pharmacol 1985. 110:203-209.
49. Tack CJ, Lutterman JA, Vervoort G, Thien T, Smits P. Activation of the sodium-potassium pump contributes to insulin-induced vasodilation in humans. Hypertension 1996. 28:426-432.
50. Gupta S, McArthur C, Grady C, Ruderman NB. Stimulation of vascular Na(+)-K(+)-ATPase activity by nitric oxide: a cGMP-independent effect. Am J Physiol 1994. 266:H2146-H2151.
51. Rand VE, Garland CJ. Endothelium-dependent relaxation to acetylcholine in the rabit basilar artery: importance of membrane hyperpolarization. Br J Pharmacol 1992. 106:143-150.
52. Dufayet D, Raccah D, Jannot MF, Coste T, Rougerie C, Vague P. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia 1998. 41:1080-1084.
53. Djemli-Shipkolye A, Gallice P, Coste T, Jannot MF, Tsimaratos M, Raccah D, Vague P. The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. Metabolism 2000. 49(7):868-872.
54. Rose AM, Valdes R Jr. Understanding the sodium pump and its relevance to disease. Clin Chem 1994. 40(9):1674-1685.
55. Lindstrom K, Johansson C, Johnsson E, Haraldsson B. Acute effects of C-peptide on the microvasculature of isolated perfused skeletal muscles and kidneys in rat. Acta Physiol Scand 1996. 156:19-25.
56. Cotter MA, Ekberg K, Wahren J, Cameron NE. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003. 52:1812-1817.
57. Johansson BL, Linde B, Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin- dependent) diabetic patients. Diabetologia 1992. 35:1151-1158.
58. Tooke JE, Lins PE, Ostergren J, Fagrell B. Skin microvascular autoregulatory responses in type I diabetes: the influence of duration and control. Int J Microcirc Clin Exp 1985. 4(3):249-256.
59. Ewald U, Tuvemo T, Rooth G. Early reduction of vascular reactivity in diabetic children detected by transcutaneous oxygen electrode. Lancet 1981. 1:1287-1288.
60. Flynn MD, Tooke JE. Aetilogy of diabetic foot ulceration. Diabetic Medicine 1992. 8:320-329.
61. Fernqvist-Forbes E, Johansson BL, Eriksson MJ. Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus. Acta Physiol Scand 2001. 172:159-165.
62. Polska E, Kolodjaschna J, Berisha F, Malec MM, Simader C, Bayerle-Eder M, Roden M, Schmetterer L. C-peptide does not affect ocular blood flow in patients with type 1 diabetes. Diabetes Care 2006. 29(9):2034-2038.
63. Luppi P, Geng X, Cifarelli V, Drain P, Trucco M. Cpeptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes. Diabetologia 2009. 52(10)2218-2228.
64. Mesquita R, Picarra B, Saldanha C, Martins e Silva J. Nitric oxide effects on human erythrocytes structural and functional properties - an in vitro study. Clin Hemorheol Microcirc 2002. 27(2):137-147.
65. Bateman RM, Jagger JE, Sharpe MD, Ellsworth ML, Mehta S, Ellis CG. Erythrocyte deformability is a nitric oxide-mediated factor in decreased capillary density during sepsis. Am J Physiol Heart Circ Physiol 2001. 280(6):H2848-H2856.